Back to search results

BTL Emsella Chair for Overactive Bladder

This study is testing the BTL Emsella Chair, a device that uses electromagnetic technology, to see if it can help people with overactive bladder (OAB). OAB causes symptoms like needing to urinate often or urgently. The Emsella Chair works by causing deep pelvic floor muscle contractions, similar to many Kegel exercises. Researchers want to compare its effectiveness against a "sham" Emsella Chair, which provides some sensation but no active treatment. The study aims to enroll 166 participants, including both men and women aged 18 and older who have had bladder symptoms for at least three months. Success will be measured by how many participants report their bladder symptoms are "moderately improved" or "markedly improved" after treatment. The study's current status is unclear.

Study design
This interventional study plans to enroll 166 participants. It compares the BTL Emsella Chair to a sham device.
What's involved
You would receive two treatments per week for a total of four weeks. You would also complete study questionnaires and communicate with staff about any side effects.
Compensation
Not stated in the trial record.
Follow-up
Your bladder symptoms will be evaluated four weeks after completing all treatments, which is at week 8 of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04873037

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

Recruiting
NAAges 18+InterventionalTreatment
Corewell Health East
~166 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:BTL Emsella ChairSham BTL Emsella Chair

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Compare the efficacy of Emsella Chair versus Sham by evaluating the proportion of subjects reporting "moderately improved" or "markedly improved" responses on the Global Response Assessment (GRA) for overall bladder symptoms.
Measured over 4 weeks after completing all treatments; week 8 of the study

Conditions

Overactive Bladder Syndrome
Overactive Bladder
Urinary Frequency
Urinary Urgency

Explore related trials

Overactive bladder syndrome

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Kenneth Peters, MD · PRINCIPAL_INVESTIGATOR · Corewell Health William Beaumont University Hospital

Who to contact

Danielle Tenney
[email protected]
248-551-3565
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.

What this trial measures

  • Compare the efficacy of Emsella Chair versus Sham by evaluating the proportion of subjects reporting "moderately improved" or "markedly improved" responses on the Global Response Assessment (GRA) for overall bladder symptoms.4 weeks after completing all treatments; week 8 of the study

    The GRA evaluates the patients' perceptions of overall improvement in symptoms on a 7-point scale (markedly worse, moderately worse, mildly worse, unchanged, slightly improved, moderately improved, markedly improved).